| scholarly article | Q13442814 |
| P2093 | author name string | Stephen D Hall | |
| Gemma L Dickinson | |||
| Bridget L Morse | |||
| Corina Loghin | |||
| Maria M Posada | |||
| Anil Kolur | |||
| Kathleen M Hillgren | |||
| Lai San Tham | |||
| Jeffrey J Alberts | |||
| Jessica Rehmel | |||
| P2860 | cites work | Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin | Q28142865 |
| Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter | Q28375489 | ||
| Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin | Q33924086 | ||
| Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites | Q34440964 | ||
| Clinical Pharmacokinetics of Atorvastatin | Q35553211 | ||
| Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin. | Q37017426 | ||
| Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption | Q38056878 | ||
| Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A. | Q38726643 | ||
| Physiologically Based Pharmacokinetic (PBPK) Modeling of Pitavastatin and Atorvastatin to Predict Drug-Drug Interactions (DDIs). | Q39178447 | ||
| effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers | Q40189578 | ||
| Effects of single nucleotide polymorphisms and haplotypes of the SLCO1B1 gene on the pharmacokinetic profile of atorvastatin in healthy Macedonian volunteers | Q40536775 | ||
| Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for atorvastatin and its metabolites | Q40791912 | ||
| Prediction of clinical irrelevance of PK differences in atorvastatin using PK/PD models derived from literature-based meta-analyses | Q40868027 | ||
| Development and Application of a Mechanistic Pharmacokinetic Model for Simvastatin and its Active Metabolite Simvastatin Acid Using an Integrated Population PBPK Approach. | Q41759104 | ||
| Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin | Q42284010 | ||
| Association of genetic variations with pharmacokinetics and lipid-lowering response to atorvastatin in healthy Korean subjects | Q42291683 | ||
| Transport vs. Metabolism: What Determines the Pharmacokinetics and Pharmacodynamics of Drugs? Insights From the Extended Clearance Model | Q42682232 | ||
| Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects. | Q43246916 | ||
| UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo | Q43268896 | ||
| Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers | Q43449319 | ||
| Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin | Q44991444 | ||
| Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. | Q45949072 | ||
| ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. | Q45993642 | ||
| Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study | Q46568560 | ||
| Effect of AGTR1 and BDKRB2 gene polymorphisms on atorvastatin metabolism in a Mexican population | Q47110674 | ||
| No Dose Adjustment is Recommended for Digoxin, Warfarin, Atorvastatin or a Combination Oral Contraceptive When Coadministered with Dulaglutide | Q48345845 | ||
| Simultaneous quantitation of atorvastatin and its two active metabolites in human plasma by liquid chromatography/(-) electrospray tandem mass spectrometry. | Q50056643 | ||
| Evaluation of Drug-Drug Interaction Potential Between Sacubitril/Valsartan (LCZ696) and Statins Using a Physiologically Based Pharmacokinetic Model. | Q50952394 | ||
| Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. | Q51634445 | ||
| Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin | Q57825140 | ||
| The interconversion kinetics, equilibrium, and solubilities of the lactone and hydroxyacid forms of the HMG-CoA reductase inhibitor, CI-981 | Q72685071 | ||
| Effect of itraconazole on the pharmacokinetics of atorvastatin | Q77057428 | ||
| Erythromycin coadministration increases plasma atorvastatin concentrations | Q77422016 | ||
| Bioavailability of amlodipine besylate/atorvastatin calcium combination tablet | Q80142362 | ||
| Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid | Q80241790 | ||
| Effect of food on the bioavailability of amlodipine besylate/atorvastatin calcium combination tablet | Q80305695 | ||
| Effect of omega-3-acid ethyl esters on steady-state plasma pharmacokinetics of atorvastatin in healthy adults | Q82593313 | ||
| Effect on the Gastrointestinal Absorption of Drugs from Different Classes in the Biopharmaceutics Classification System, When Treating with Liraglutide | Q86350083 | ||
| UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone | Q86582913 | ||
| P433 | issue | 9 | |
| P304 | page(s) | 664-675 | |
| P577 | publication date | 2019-08-01 | |
| P1433 | published in | CPT: pharmacometrics & systems pharmacology | Q27724610 |
| P1476 | title | Physiologically-Based Pharmacokinetic Modeling of Atorvastatin Incorporating Delayed Gastric Emptying and Acid-to-Lactone Conversion | |
| P478 | volume | 8 |
| Q90146101 | A hybrid model to evaluate the impact of active uptake transport on hepatic distribution of atorvastatin in rats | cites work | P2860 |
Search more.